When it comes to managing your self-managed super fund (SMSF), the goal is clear: grow your wealth, protect your capital, and generate reliable returns over the long term.

That's why choosing the right ASX shares for your SMSF is so important. You're not just investing for the next year or two — you're building a portfolio that could fund decades of retirement.

With that in mind, listed below are a handful of fantastic ASX shares that combine quality, consistency, and long-term growth potential. Here's what analysts are tipping as buys:

CSL Ltd (ASX: CSL)

CSL is a global biotechnology giant and one of the most consistent long-term performers on the Australian share market. It develops plasma therapies, vaccines, and other life-saving treatments. Its world-class R&D pipeline and strong global demand for immunoglobulin therapies make it a compounding machine with a deep moat.

Goldman Sachs has a buy rating and $304.60 price target on its shares.

Goodman Group (ASX: GMG)

Goodman is a property powerhouse specialising in logistics, ecommerce, and data centre infrastructure. With blue chip customers, this ASX share is well-positioned to benefit from the global shift toward digital infrastructure and supply chain modernisation.

Last week, Citi reaffirmed its buy rating and $40.00 price target on the company's shares.

REA Group Ltd (ASX: REA)

Another ASX share that could be a top pick for an SMSF is REA Group. It is the digital advertising juggernaut behind the dominant realestate.com.au website. It benefits from network effects, pricing power, and growing global operations, including in India.

Goldman Sachs is also a big fan of REA Group. It has a buy rating and $269.00 price target on its shares.

Telix Pharmaceuticals Ltd (ASX: TLX)

For those with an appetite for growth and innovation, Telix offers exposure to the cutting edge of radiopharmaceutical technology. Its flagship product, Illuccix, is already generating revenue, and its pipeline is expanding fast. While higher risk than others on this list, this ASX share could be a standout biotech story over the next decade.

Bell Potter is bullish on Telix. It has a buy rating and $34.00 price target on its shares.

Xero Ltd (ASX: XRO)

Finally, Xero could be a top ASX share to buy for an SMSF. It is a global cloud accounting software provider, helping small and medium businesses manage their affairs with ease. With a sticky, subscription-based model and a large growth runway, Xero is a prime example of a scalable software business that's still expanding.

Goldman Sachs also rates it highly. It has a buy rating and $205.00 price target on its shares.